WallStreetZenWallStreetZen

NASDAQ: RDHL
Redhill Biopharma Ltd Stock

$0.14+0.00 (+0%)
Updated Mar 22, 2023
RDHL Price
$0.14
Fair Value Price
$9.67
Market Cap
$7.96M
52 Week Low
$0.13
52 Week High
$3.10
P/E
-0.09x
P/B
-0.17x
P/S
0.42x
PEG
N/A
Dividend Yield
N/A
Revenue
$76.21M
Earnings
-$88.92M
Gross Margin
39.9%
Operating Margin
-65.88%
Profit Margin
-116.7%
Debt to Equity
-4.42
Operating Cash Flow
-$42M
Beta
1.08
Next Earnings
Mar 24, 2023
Ex-Dividend
N/A
Next Dividend
N/A

RDHL Overview

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and has completed Phase 2 studies for irritable bowel syndrome with diarrhea; and RHB-106, an encapsulated formulation for bowel preparation, which is preparing for Phase 2/3 study. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel.

Zen Score

Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how RDHL scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

RDHL ($0.14) is undervalued by 98.55% relative to our estimate of its Fair Value price of $9.67 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
RDHL ($0.14) is significantly undervalued by 98.55% relative to our estimate of its Fair Value price of $9.67 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
RDHL is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more RDHL due diligence checks available for Premium users.

Be the first to know about important RDHL news, forecast changes, insider trades & much more!

RDHL News

Valuation

RDHL fair value

Fair Value of RDHL stock based on Discounted Cash Flow (DCF)
Price
$0.14
Fair Value
$9.67
Undervalued by
98.55%
RDHL ($0.14) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
RDHL ($0.14) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
RDHL is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

RDHL price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.09x
Industry
17.73x
Market
22.44x

RDHL price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
-0.17x
Industry
1.79x

RDHL's financial health

Profit margin

Revenue
$17.6M
Net Income
-$35.7M
Profit Margin
-203.4%
RDHL's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
RDHL's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$157.2M
Liabilities
$203.2M
Debt to equity
-4.42
RDHL's short-term liabilities ($193.53M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
RDHL's short-term assets ($83.10M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
RDHL's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
RDHL's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$6.0M
Investing
-$22.0k
Financing
-$5.7M
RDHL's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

RDHL vs Pharmaceutical Stocks

TickerMarket Cap1d %P/EP/B
RDHL$7.96M0.00%-0.09x-0.17x
EVOK$8.79M-15.16%-1.00x2.15x
JUPW$9.04M+12.53%-0.34x1.06x
ATNX$9.18M+3.92%-0.07x-1.41x
ALIM$9.46M-17.68%-0.51x-0.52x

Redhill Biopharma Stock FAQ

What is Redhill Biopharma's quote symbol?

NASDAQ: RDHL) Redhill Biopharma trades on the NASDAQ under the ticker symbol RDHL. Redhill Biopharma stock quotes can also be displayed as NASDAQ: RDHL.

If you're new to stock investing, here's how to buy Redhill Biopharma stock.

What is the 52 week high and low for Redhill Biopharma (NASDAQ: RDHL)?

(NASDAQ: RDHL) Redhill Biopharma's 52-week high was $3.10, and its 52-week low was $0.13. It is currently -95.48% from its 52-week high and 11.11% from its 52-week low.

How much is Redhill Biopharma stock worth today?

(NASDAQ: RDHL) Redhill Biopharma currently has 568,308,000 outstanding shares. With Redhill Biopharma stock trading at $0.14 per share, the total value of Redhill Biopharma stock (market capitalization) is $7.96M.

Redhill Biopharma stock was originally listed at a price of $11.10 in Jan 7, 2013. If you had invested in Redhill Biopharma stock at $11.10, your return over the last 10 years would have been -98.74%, for an annualized return of -35.42% (not including any dividends or dividend reinvestments).

How much is Redhill Biopharma's stock price per share?

(NASDAQ: RDHL) Redhill Biopharma stock price per share is $0.14 today (as of Mar 22, 2023).

What is Redhill Biopharma's Market Cap?

(NASDAQ: RDHL) Redhill Biopharma's market cap is $7.96M, as of Mar 24, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Redhill Biopharma's market cap is calculated by multiplying RDHL's current stock price of $0.14 by RDHL's total outstanding shares of 568,308,000.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.